Liraglutide
- Generic Name
- Liraglutide
- Brand Names
- Saxenda, Victoza, Xultophy
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 204656-20-2
- Unique Ingredient Identifier
- 839I73S42A
- Background
Victoza contains liraglutide, a synthetic analog of human glucagon-like peptide-1(GLP-1) and acts as a GLP-1 receptor agonist. Liraglutide is 97% similar to native human GLP-1, differing primarily by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining...
- Indication
Saxenda, a formulation of liraglutide intended for weight loss, is indicated as an adjunct to diet and exercise for chronic weight management in adult patients who are obese (BMI≥30 kg/m), or who are overweight (BMI≥27 kg/m) and have at least one weight-related comorbidity. It is also indicated for chronic weight management in pediatric patients ≥12 years ol...
- Associated Conditions
- Major Adverse Cardiovascular Events, Type 2 Diabetes Mellitus
- Associated Therapies
- Chronic Weight Management therapy
Cooperation of Insulin and GLP-1 on Myocardial Glucose Uptake
- Conditions
- Interventions
- First Posted Date
- 2010-11-02
- Last Posted Date
- 2019-08-07
- Lead Sponsor
- Indiana University
- Target Recruit Count
- 30
- Registration Number
- NCT01232946
- Locations
- 🇺🇸
Indiana Clinical Research Center, Indianapolis, Indiana, United States
Observational Study on Efficacy and Safety of Liraglutide in Subjects With Type 2 Diabetes
- First Posted Date
- 2010-10-22
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3152
- Registration Number
- NCT01226966
- Locations
- 🇫🇷
Novo Nordisk Investigational Site, Paris La défense cedex, France
A Post Marketing Surveillance (PMS) Study of Liraglutide in Subjects With Type 2 Diabetes Mellitus in India
- First Posted Date
- 2010-09-30
- Last Posted Date
- 2016-12-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1386
- Registration Number
- NCT01212133
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Bangalore, India
Efficacy and Safety of Liraglutide in Subjects With Type 1 Diabetes Undergoing Islet Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2010-09-21
- Last Posted Date
- 2017-03-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3
- Registration Number
- NCT01206101
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
- Conditions
- Interventions
- First Posted Date
- 2010-08-10
- Last Posted Date
- 2019-07-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 9341
- Registration Number
- NCT01179048
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, West Midlands, United Kingdom
Effects of Lixisenatide Compared to Liraglutide on the Postprandial Plasma Glucose in Patients With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2010-08-04
- Last Posted Date
- 2016-11-28
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 148
- Registration Number
- NCT01175473
- Locations
- 🇩🇪
Sanofi-Aventis Investigational Site Number 276004, Kiel, Germany
🇩🇪Sanofi-Aventis Investigational Site Number 276002, Mainz, Germany
🇩🇪Sanofi-Aventis Investigational Site Number 276006, Berlin, Germany
A Study to Determine the Efficacy and Safety of Albiglutide as Compared With Liraglutide.
- Conditions
- Interventions
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2017-02-23
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 841
- Registration Number
- NCT01128894
- Locations
- 🇬🇧
GSK Investigational Site, Swansea, United Kingdom
Efficacy Assessment of Insulin Glargine Versus LiraglutidE After Oral Agents Failure
- Conditions
- Interventions
- First Posted Date
- 2010-05-05
- Last Posted Date
- 2014-04-11
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 978
- Registration Number
- NCT01117350
- Locations
- 🇺🇸
Investigational Site Number 840026, Longmont, Colorado, United States
🇺🇸Investigational Site Number 840007, Dallas, Texas, United States
🇺🇸Investigational Site Number 840020, Uniontown, Pennsylvania, United States
Safety and Efficacy of Exenatide Once Weekly Versus Liraglutide in Subjects With Type 2 Diabetes
- Conditions
- Interventions
- First Posted Date
- 2009-12-10
- Last Posted Date
- 2015-04-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 912
- Registration Number
- NCT01029886
- Locations
- 🇨🇳
Research Site, Yung-Kang, Tainan, Taiwan
🇷🇴Research site, Oradea, Romania
A Trial to Assess the Effect of Liraglutide on Blood Triglyceride (Fat) Levels After a Meal in Type 2 Diabetics
- Conditions
- Interventions
- First Posted Date
- 2009-10-12
- Last Posted Date
- 2017-01-26
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 20
- Registration Number
- NCT00993304
- Locations
- 🇩🇰
Novo Nordisk Investigational Site, Aarhus C, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.